# Trade Mark Journal No.2026/024 12 June 2026

## WO0000001918922 (5)

Office of origin: United States of America

Date of International Registration:29 April 2026
Date of designation in the UK: 29 April 2026

International priority date claimed: 30 October 2025 (United States of America) (99471611)

Class 5
  Pharmaceutical preparations for the treatment and prevention of achondroplasia and hypochondroplasia.

Bridgebio Pharma, Inc.

Representative: Jessica L. Rothstein Goodwin Procter LLP, 620 Eighth Avenue, New York NY 10018, UNITED STATES OF AMERICA